Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease

Biomarkers relevant to the pre-dementia stages of Alzheimer’s disease are needed. Using MEG, PET, and MRI, Nakamura et al. disentangle resting state regional spectral patterns in cognitively normal subjects and individuals with mild cognitive impairment into MEG signatures related to Aβ deposition, disease progression, or changes non-specific to Alzheimer’s disease.

[1]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[2]  Jurgen Fripp,et al.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. , 2013, JAMA neurology.

[3]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[4]  C. Rowe,et al.  Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[5]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[6]  J. Morris.  Early-stage and preclinical Alzheimer disease. , 2005, Alzheimer disease and associated disorders.

[7]  C. Rowe,et al.  Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study , 2016, The Lancet Neurology.

[8]  W. Drongelen,et al.  Localization of brain electrical activity via linearly constrained minimum variance spatial filtering , 1997, IEEE Transactions on Biomedical Engineering.

[9]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[10]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  L. Prichep,et al.  Quantitative EEG and Electromagnetic Brain Imaging in Aging and in the Evolution of Dementia , 2007, Annals of the New York Academy of Sciences.

[12]  C. Stam.  Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders , 2010, Journal of the Neurological Sciences.

[13]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[14]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[15]  Kaj Blennow,et al.  Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years , 2010, Neurobiology of Aging.

[16]  Claudio Del Percio,et al.  Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study , 2006, Clinical Neurophysiology.

[17]  Cornelis J. Stam,et al.  EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects , 2017, Neurobiology of Aging.

[18]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[19]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[20]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[21]  C. Rowe,et al.  Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.

[22]  Guido Rodriguez,et al.  Quantitative Electroencephalography and Regional Cerebral Blood Flow: Discriminant Analysis between Alzheimer’s Patients and Healthy Controls , 1998, Dementia and Geriatric Cognitive Disorders.

[23]  Michael D. Greicius,et al.  Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. , 2011, Cerebral cortex.

[24]  Juhani Partanen,et al.  Spectral analysis of EEG in Alzheimer's disease: Relation to apolipoprotein E polymorphism , 1996, Neurobiology of Aging.

[25]  A. Nordberg,et al.  Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer’s disease , 2000, Neurobiology of Aging.

[26]  A. Nakamura,et al.  Early functional network alterations in asymptomatic elders at risk for Alzheimer’s disease , 2017, Scientific Reports.

[27]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[28]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[29]  A. Barabash,et al.  Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study. , 2016, Journal of Alzheimer's disease : JAD.

[30]  R. Oostenveld,et al.  Nonparametric statistical testing of EEG- and MEG-data , 2007, Journal of Neuroscience Methods.

[31]  H. Matsuda.  Voxel-based Morphometry of Brain MRI in Normal Aging and Alzheimer's Disease. , 2013, Aging and disease.

[32]  Roberto Hornero,et al.  MEG spectral profile in Alzheimer's disease and mild cognitive impairment , 2006, Clinical Neurophysiology.

[33]  H Matsuda,et al.  Automatic Voxel-Based Morphometry of Structural MRI by SPM8 plus Diffeomorphic Anatomic Registration Through Exponentiated Lie Algebra Improves the Diagnosis of Probable Alzheimer Disease , 2012, American Journal of Neuroradiology.

[34]  Isidro Ferrer,et al.  Diminished Perisomatic GABAergic Terminals on Cortical Neurons Adjacent to Amyloid Plaques , 2009, Front. Neuroanat..

[35]  Claudio Babiloni,et al.  Electroencephalographic Rhythms in Alzheimer's Disease , 2011, International journal of Alzheimer's disease.

[36]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Bajo,et al.  MEG spectral analysis in subtypes of mild cognitive impairment , 2014, AGE.

[38]  C. Stam,et al.  Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity , 2013, Neurobiology of Aging.

[39]  Mark A Mintun,et al.  Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. , 2009, Archives of neurology.

[40]  Vesna Jelic,et al.  Association between EEG Abnormalities and CSF Biomarkers in a Memory Clinic Cohort , 2013, Dementia and Geriatric Cognitive Disorders.

[41]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[43]  A. Fagan,et al.  Suspected non-Alzheimer disease pathophysiology — concept and controversy , 2016, Nature Reviews Neurology.

[44]  Robert Oostenveld,et al.  FieldTrip: Open Source Software for Advanced Analysis of MEG, EEG, and Invasive Electrophysiological Data , 2010, Comput. Intell. Neurosci..

[45]  L S Honig,et al.  Aging and Alzheimer's disease: lessons from the Nun Study. , 1998, The Gerontologist.

[46]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[47]  D. Perani,et al.  Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. , 2005, Archives of neurology.

[48]  Akinori Nakamura,et al.  Source analysis of spontaneous magnetoencephalograpic activity in healthy aging and mild cognitive impairment: influence of apolipoprotein E polymorphism. , 2014, Journal of Alzheimer's disease : JAD.

[49]  Li Yao,et al.  Impairment and compensation coexist in amnestic MCI default mode network , 2010, NeuroImage.

[50]  H. Amièva,et al.  Incidence and outcome of mild cognitive impairment in a population-based prospective cohort , 2002, Neurology.

[51]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[52]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[53]  Alberto Fernández,et al.  Magnetoencephalographic parietal delta dipole density in mild cognitive impairment: preliminary results of a method to estimate the risk of developing Alzheimer disease. , 2006, Archives of neurology.

[54]  Ricardo Bruña,et al.  Alpha-Band Hypersynchronization in Progressive Mild Cognitive Impairment: A Magnetoencephalography Study , 2014, The Journal of Neuroscience.

[55]  P. Tariot,et al.  Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. , 2016, The journal of prevention of Alzheimer's disease.

[56]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[57]  H. Arai,et al.  18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[58]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[59]  D. Schacter,et al.  The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.

[60]  José Luis Molinuevo,et al.  Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. , 2016, The lancet. Psychiatry.

[61]  J. Sirviö,et al.  Relationship between the cortical choline acetyltransferase content and EEG delta-power , 1990, Neuroscience Research.

[62]  T. Dierks,et al.  EEG slowing and cerebrospinal fluid tau levels in patients with cognitive decline , 1998, Neuroreport.

[63]  Alberto Fernández,et al.  Correlations of hippocampal atrophy and focal low-frequency magnetic activity in Alzheimer disease: volumetric MR imaging-magnetoencephalographic study. , 2003, AJNR. American journal of neuroradiology.

[64]  S. Rossi,et al.  Clinical neurophysiology of aging brain: From normal aging to neurodegeneration , 2007, Progress in Neurobiology.

[65]  D. Hill,et al.  Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration , 2016, Neurology.

[66]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[67]  David T. Jones,et al.  Cascading network failure across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[68]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[69]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[70]  Keith A. Johnson,et al.  Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. , 2016, JAMA neurology.

[71]  Alberto Fernández,et al.  MEG delta mapping along the healthy aging-Alzheimer's disease continuum: diagnostic implications. , 2013, Journal of Alzheimer's disease : JAD.

[72]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[73]  W. Klunk,et al.  Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. , 2014, Brain : a journal of neurology.

[74]  A. Nakamura,et al.  Novel plasma biomarker surrogating cerebral amyloid deposition , 2014, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[75]  Cornelis J. Stam,et al.  Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer’s Disease. An MEG Study with Virtual Electrodes , 2016, Front. Hum. Neurosci..